Share
When you hear the words Alzheimer's disease, what do you think of? The truth is, the picture most of us have of the disease is incomplete. Alzheimer's disease doesn't start when someone starts to lose their memory. It actually starts years – sometimes decades – earlier. The Rethinking Alzheimer's Disease Podcast is an engaging, narrative-style podcast miniseries for those curious or motivated to learn about Alzheimer’s disease. Perhaps you have a family member with Alzheimer’s disease, or ca ...
…
continue reading
Manage episode 521489309 series 2592278
Content provided by American Society of Hematology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by American Society of Hematology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://staging.podcastplayer.com/legal.
In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Lorenzo Falchi and Robert Levy on their latest papers published in Blood Journal. Dr. Falchi discusses his work on an open-label, multicenter phase 1b/2 study evaluating fixed-duration epcoritamab with rituximab and lenalidomide in 108 patients with relapsed or refractory follicular lymphoma. Dr. Levy shares his work on demonstrating that in vivo expansion of Tregs in recipients prior to transplant is possible by activating TNFRSF25 (also known as death receptor 3) in combination with low-dose interleukin-2 in preclinical models. Both papers showed impressive and promising results for the treatment of lymphoma and GVHD.
Featured Articles
354 episodes
))
